Efficacy and Safety of HB0034 in Patients with Generalized Pustular Psoriasis (GPP)
Status:
RECRUITING
Trial end date:
2025-11-30
Target enrollment:
Participant gender:
Summary
This is a phase II, multicenter, double-blind, randomized, placebo parallel-controlled clinical trial to evaluate the efficacy and safety of HB0034 in patients with generalized pustular psoriasis (GPP) presenting with an acute flare of moderate to severe intensity.